Revvity, Inc. (RVTY)

Over the past six months, Revvity's stock has trended down by 21.23%. Key events include the Q1 2025 earnings report with better-than-expected revenue and EPS, an upgrade from UBS, a $1,000 million equity buyback announcement, and a quarterly dividend declaration. Analyst sentiment is predominantly positive, although the company has faced weak demand in the short term.

Information directly detailing the overall demand seasonality for all of Revvity, Inc.'s products and services is not explicitly available. There is a normal seasonality between the third and fourth quarters related to instrumentation, and the software business experiences renewal timing. The Reproductive Health business has shown steady demand, while the company has faced weak market demand in the short term. Historically, July has shown a chance of being a green month for RVTY stock.

Revvity, Inc., formerly PerkinElmer, Inc., is a global provider of health sciences solutions operating in the Healthcare sector, specifically within the Medical Diagnostics & Research industry. The company is segmented into Life Sciences, offering instruments, reagents, and technologies for biomedical research, and Diagnostics, providing products for early detection of genetic disorders and infectious disease testing. Revvity's products and services are used by pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies.

Revvity, Inc. has a global presence, with its headquarters in Waltham, Massachusetts, U.S., and operations in Asia, Europe, and the Americas.

Revvity's brand reputation in the past year appears generally positive, particularly following its rebranding from PerkinElmer, Inc. Strategic partnerships, innovations in genomics and diagnostics, a focus on AI, and acquisitions have positively impacted its reputation.

Revvity is primarily owned by institutional shareholders (approximately 95.76%), with insiders holding about 2.70% and retail investors 1.54%. Major institutional owners include T. Rowe Price Investment Management, Inc., Vanguard Group Inc., and BlackRock, Inc. The largest individual shareholder is Alexis P. Michas.